Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab biomarker study in KRAS-mutated NSCLC
NL-OMON45880Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Early discrimination of responders versus non-responders. Started Aug 2017; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45880.